Oscar Health (OSCR) Q4 2025 earnings review
The 'Reset' Year Ends in Deep Red, But 2026 Guidance is Massive
Oscar Health closed FY25 with a financially disastrous fourth quarter—MLR spiked to 95.4% and the company swung to a $353M net loss. However, the narrative is entirely focused on a bullish pivot to 2026. Management characterizes 2025 as a necessary 'reset' where they absorbed high morbidity costs. The headline story is the FY26 outlook: Membership has surged to ~3.4 million (up from 2.04M in Q4), and Revenue is guided to $18.7B–$19.0B (+60% YoY). If they achieve the guided return to profitability ($250M–$450M operating earnings), the thesis holds; if the 2025 morbidity issues persist, the capital structure will be tested.
🐂 Bull Case
The company announced ~3.4 million members for the 2026 plan year, a massive jump from 2.04 million at year-end 2025. Coupled with aggressive pricing (~28% rate hikes), this drives the revenue guidance to ~$18.9B, a 60% increase year-over-year.
Oscar pushed through significant rate increases for 2026 to cover observed morbidity trends. If the premiums hold and the risk pool stabilizes as predicted, the projected 400-500 bps improvement in MLR is achievable.
🐻 Bear Case
Q4 Medical Loss Ratio hit 95.4%, a shocking deterioration from 88.1% a year ago. Management blames risk adjustment and morbidity, but such a high ratio suggests a potential loss of control over claims costs or pricing models in the short term.
The company burned significant cash in FY25 (Net Loss $443M). While they secured a new $475M revolving credit facility in Feb 2026, the margin for error is thin. If 2026 MLR misses the optimistic 82-83% target, liquidity concerns will resurface.
⚖️ Verdict: ⚪
Neutral/Wait-and-See. The growth numbers (3.4M members) are undeniable, but the Q4 financial performance was abysmal. The investment case rests entirely on management's promise that 2026 pricing corrects the 2025 morbidity issues. Until MLR normalizes in Q1/Q2 2026, this is a high-beta execution play.
Key Themes
Medical Loss Ratio Blowout
The degradation in unit economics was severe. FY25 MLR ended at 87.4%, significantly missing the original targets, with Q4 spiking to 95.4%. Management cites 'higher average market morbidity' and 'net risk adjustment transfer accrual.' The concern is whether the 2026 pricing adjustments are sufficient to combat a trend that accelerated violently at year-end.
Hyper-Growth in 2026 Enrollment
Despite raising prices significantly (approx 28%), Oscar grew membership to ~3.4 million for the 2026 plan year (implied from headline vs 2.04M at Q4 end). This validates the 'Agentic AI' and user experience thesis—consumers are choosing Oscar even at higher price points, or competitors have exited/priced themselves out.
SG&A Leverage Continues
A bright spot amidst the MLR chaos. The SG&A expense ratio improved to 17.5% for FY25 (down from 19.1% in FY24). Guidance for FY26 is 15.8%–16.3%. As revenue scales to $19B, Oscar is proving it can control administrative costs, which is critical if medical margins remain compressed.
Capital Structure Fortification
Recognizing the cash burn from 2025, Oscar executed a $475M secured revolving credit facility on Feb 6, 2026. This was a necessary defensive move to ensure they can support the capital requirements of adding ~1.4 million new members in 2026.
Agentic AI Features
CEO Mark Bertolini explicitly credited 'agentic AI features' alongside affordable products for the record membership growth. While financial details on AI ROI are scarce, the ability to scale to 3.4M members while projecting lower SG&A ratios suggests tech-enabled efficiency is real.
Macro Risk: ACA Marketplace Instability
The sheer volatility in risk adjustment transfers ($316M hit in Q2, further deterioration in Q4) highlights the instability of the ACA individual market risk pool. The 'reset' narrative implies the entire market got sicker in 2025. If this trend underestimates the 2026 acuity, the guidance is at risk.
Other KPIs
Accelerating. Up 27.5% YoY from $9.2B in FY24. Growth was driven by membership increases but partially offset by higher risk adjustment transfer accruals (which reduce net revenue).
Reversing. Swung from a profit of $199M in FY24 to a significant loss. The deterioration accelerated in Q4, contributing $(308)M of loss in a single quarter.
Stable/Positive. Despite the net loss, operating cash flow remained positive due to the timing of payables (Risk Adjustment Transfer Payable increased by over $1B). This is a temporary working capital benefit that will eventually result in cash outflows when settlements occur.
Guidance
Accelerating. Implies ~60% YoY growth. This is driven by the membership surge to 3.4M and the ~28% premium rate increases. This figure is significantly higher than previous growth trends.
Reversing (Improving). Management expects a sharp improvement from FY25's 87.4% and Q4's 95.4%. This relies on the assumption that 2026 pricing accurately captured the morbidity spike.
Reversing. Guides for a return to profitability after a $(396)M loss in FY25. The midpoint implies a ~$750M swing in operating performance year-over-year.
Key Questions
Bridge the Q4 to FY26 MLR Gap
Q4 MLR was 95.4%. You are guiding to ~83% for FY26. While pricing is up 28%, medical trend is also active. Can you walk us through the specific components (pricing, utilization management, acuity mix) that bridge this massive 1,200 basis point improvement?
Risk Adjustment Volatility
2025 was plagued by negative surprises in risk adjustment transfer payables. What changes have you made to your reserving methodology or data visibility to ensure we don't see another nine-figure negative surprise in late 2026?
Capital Adequacy for 3.4M Members
With membership growing 60%+, statutory capital requirements will rise significantly. Does the new $475M revolver provide enough cushion to fund this growth if MLR comes in at the high end of guidance (e.g., 84-85%)?
Adverse Selection Risk
You raised rates ~28%. Yet membership grew by ~1.4 million. In an insurance market, rapid growth at higher prices often signals that competitors priced even higher or exited. Are you concerned you have aggregated a sicker-than-average population from exiting peers?